• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

α-肾上腺素能受体亚型

Alpha-adrenoceptor subtypes.

作者信息

Civantos Calzada B, Aleixandre de Artiñano A

机构信息

Departamento de Farmacología, Facultad de Medicina, Universidad Complutense de Madrid, Spain.

出版信息

Pharmacol Res. 2001 Sep;44(3):195-208. doi: 10.1006/phrs.2001.0857.

DOI:10.1006/phrs.2001.0857
PMID:11529686
Abstract

Different studies have led to our present knowledge of the membrane receptors responsible for mediating the responses to the endogenous catecholamines. These receptors were initially differentiated into alpha - and beta-adrenoceptors. Alpha-adrenoceptors mediate most excitatory functions, and were in turn differentiated in the 1970s into alpha(1)- and alpha(2)-adrenoceptors. The alpha(1)-adrenoceptor type usually mediates responses in the effector organ. The alpha(2)-adrenoceptor type is located presynaptically and regulates the release of the neurotransmitter but it is also present in postsynaptical locations. Both alpha-adrenoceptors are important for the control of vascular tone, but we now know that neither alpha(1)- nor alpha(2)-adrenoceptors constitute homogeneous groups. Each alpha-adrenoceptor type can be subdivided into different subtypes and in this review we have turned our attention to these. The alpha(1)- and the alpha(2)-adrenoceptor subtypes were previously defined pharmacologically by functional and binding studies, and later they were also isolated and identified using cloning methods. In fact, the study of alpha-adrenoceptors was revolutionized by the techniques of molecular biology which permitted us to establish the present classification. The present classification of alpha(1)-adrenoceptors stands as follows: alpha(1A)-adrenoceptor subtype (cloned alpha(1c) and redesignated alpha(1a/c)), alpha(1B)-adrenoceptor subtype (cloned alpha(1b)) and alpha(1D)-adrenoceptor subtype (cloned alpha(1d) and redesignated alpha(1a/d)). It has not been easy to establish the distribution of these alpha(1)-adrenoceptor subtypes in the various organs and tissues, or to define the functional response mediated by each one in the different species studied. Nevertheless it seems that the alpha(1A)-adrenoceptor subtype is more implicated in the maintenance of vascular basal tone and of arterial blood pressure in conscious animals, and the alpha(1B)-adrenoceptor subtype participates more in responses to exogenous agonists. It has also been observed that the expression of the alpha(1B)-adrenoceptor subtype can be modified in pathological situations and particular attention has been paid to the regulation of expression of this receptor. The present classification of alpha(2)-adrenoceptors stands as follows: alpha(2A/D)-adrenoceptor subtype (today it is accepted that the alpha(2A)-adrenoceptor subtype and the alpha(2D)-adrenoceptor subtype are the same receptor but they were identified in different species: the alpha(2A) in human and the alpha(2D) in rat); alpha(2B)-adrenoceptor subtype (cloned alpha(2b)) and alpha(2C)-adrenoceptor subtype (cloned alpha(2c)). Today we know that the alpha(2A/D)- and alpha(2B)-adrenoceptor subtypes in particular control arterial contraction, and that the alpha(2C)-adrenoceptor subtype is responsible above all for venous vasoconstriction. We also know that the alpha(2 A/D)-adrenoceptor subtype fundamentally mediates the central effects of the alpha(2)-adrenoceptor agonists. Despite the validity of the above-mentioned classification of the alpha(1)- and alpha(2)-adrenoceptors, it seems clear that the contractions of a large number of tissues including smooth muscle are mediated by more than one alpha-adrenoceptor subtype. Moreover, few ligands recognise only one alpha-adrenoceptor subtype and the lack of specifity in the different drugs for each one limits their administration in vivo and their therapeutic use.

摘要

不同的研究使我们对介导对内源性儿茶酚胺反应的膜受体有了目前的认识。这些受体最初被区分为α-和β-肾上腺素能受体。α-肾上腺素能受体介导大多数兴奋性功能,并且在20世纪70年代又被进一步区分为α(1)-和α(2)-肾上腺素能受体。α(1)-肾上腺素能受体类型通常介导效应器器官中的反应。α(2)-肾上腺素能受体类型位于突触前,调节神经递质的释放,但它也存在于突触后位置。两种α-肾上腺素能受体对血管张力的控制都很重要,但我们现在知道α(1)-和α(2)-肾上腺素能受体都不构成同质群体。每种α-肾上腺素能受体类型都可细分为不同的亚型,在本综述中我们将注意力转向了这些亚型。α(1)-和α(2)-肾上腺素能受体亚型以前通过功能和结合研究在药理学上进行定义,后来也通过克隆方法进行分离和鉴定。事实上,分子生物学技术彻底改变了α-肾上腺素能受体的研究,使我们能够建立目前的分类。目前α(1)-肾上腺素能受体的分类如下:α(1A)-肾上腺素能受体亚型(克隆的α(1c)并重新命名为α(1a/c))、α(1B)-肾上腺素能受体亚型(克隆的α(1b))和α(1D)-肾上腺素能受体亚型(克隆的α(1d)并重新命名为α(1a/d))。确定这些α(1)-肾上腺素能受体亚型在各种器官和组织中的分布,或确定在不同研究物种中每种亚型介导的功能反应并非易事。然而,似乎α(1A)-肾上腺素能受体亚型在维持清醒动物的血管基础张力和动脉血压方面作用更大,而α(1B)-肾上腺素能受体亚型更多地参与对外源性激动剂的反应。还观察到α(1B)-肾上腺素能受体亚型的表达在病理情况下可被改变,并且对该受体表达的调节给予了特别关注。目前α(2)-肾上腺素能受体的分类如下:α(2A/D)-肾上腺素能受体亚型(如今人们认为α(2A)-肾上腺素能受体亚型和α(2D)-肾上腺素能受体亚型是同一受体,但它们在不同物种中被鉴定出来:人类中的α(2A)和大鼠中的α(2D));α(2B)-肾上腺素能受体亚型(克隆的α(2b))和α(2C)-肾上腺素能受体亚型(克隆的α(2c))。如今我们知道,特别是α(2A/D)-和α(2B)-肾上腺素能受体亚型控制动脉收缩,而α(2C)-肾上腺素能受体亚型主要负责静脉血管收缩。我们还知道α(2A/D)-肾上腺素能受体亚型从根本上介导α(2)-肾上腺素能受体激动剂的中枢效应。尽管上述α(1)-和α(2)-肾上腺素能受体的分类是有效的,但很明显,包括平滑肌在内大量组织的收缩是由不止一种α-肾上腺素能受体亚型介导的。此外,很少有配体只识别一种α-肾上腺素能受体亚型,并且不同药物对每种亚型缺乏特异性限制了它们在体内的给药及其治疗用途。

相似文献

1
Alpha-adrenoceptor subtypes.α-肾上腺素能受体亚型
Pharmacol Res. 2001 Sep;44(3):195-208. doi: 10.1006/phrs.2001.0857.
2
Characterization of the postjunctional alpha 2C-adrenoceptor mediating vasoconstriction to UK14304 in porcine pulmonary veins.猪肺静脉中介导对UK14304产生血管收缩作用的接头后α2C肾上腺素能受体的特性
Br J Pharmacol. 2007 May;151(2):186-94. doi: 10.1038/sj.bjp.0707221. Epub 2007 Mar 20.
3
Functional evidence equating the pharmacologically-defined alpha 1A- and cloned alpha 1C-adrenoceptor: studies in the isolated perfused kidney of rat.药理学定义的α1A-与克隆的α1C-肾上腺素能受体等同的功能证据:大鼠离体灌注肾研究。
Br J Pharmacol. 1995 May;115(2):283-94. doi: 10.1111/j.1476-5381.1995.tb15875.x.
4
Failure of AH11110A to functionally discriminate between alpha(1)-adrenoceptor subtypes A, B and D or between alpha(1)- and alpha(2)-adrenoceptors.AH11110A在功能上无法区分α(1)-肾上腺素能受体亚型A、B和D,也无法区分α(1)-和α(2)-肾上腺素能受体。
Eur J Pharmacol. 2001 Mar;415(2-3):265-76. doi: 10.1016/s0014-2999(01)00835-4.
5
Classification of alpha 1-adrenoceptor subtypes.α1肾上腺素能受体亚型的分类。
Naunyn Schmiedebergs Arch Pharmacol. 1995 Jul;352(1):1-10. doi: 10.1007/BF00169183.
6
Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries.溴莫尼定在猪睫状动脉中通过强效α(2A)-肾上腺素能受体介导的血管收缩作用。
Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55.
7
Pharmacological properties of the cloned alpha 1A/D-adrenoceptor subtype are consistent with the alpha 1A-adrenoceptor characterized in rat cerebral cortex and vas deferens.克隆的α1A/D-肾上腺素能受体亚型的药理学特性与在大鼠大脑皮层和输精管中鉴定出的α1A-肾上腺素能受体一致。
Br J Pharmacol. 1994 Apr;111(4):1003-8. doi: 10.1111/j.1476-5381.1994.tb14843.x.
8
RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.RS - 17053(N - [2 - (2 - 环丙基甲氧基苯氧基)乙基]-5 - 氯 - α,α - 二甲基 - 1H - 吲哚 - 3 - 乙胺盐酸盐),一种选择性α1A - 肾上腺素能受体拮抗剂,对人前列腺中的功能性α1 - 肾上腺素能受体显示出低亲和力:对肾上腺素能受体分类的意义。
Mol Pharmacol. 1996 Feb;49(2):209-15.
9
History and nomenclature of alpha1-adrenoceptors.α1肾上腺素能受体的历史与命名
Eur Urol. 1999;36 Suppl 1:2-6.
10
Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists.α-1肾上腺素能受体拮抗剂的比较性α-1肾上腺素能受体亚型选择性和功能性尿选择性
J Pharmacol Exp Ther. 1997 Jul;282(1):228-35.

引用本文的文献

1
Adrenergic receptor subtypes differentially influence acrolein-induced ventilatory, vascular leakage, and inflammatory responses.肾上腺素能受体亚型对丙烯醛诱导的通气、血管渗漏及炎症反应有不同影响。
Toxicol Appl Pharmacol. 2025 May;498:117303. doi: 10.1016/j.taap.2025.117303. Epub 2025 Mar 16.
2
Mitochondrial Functioning: Front and Center in Defining Psychosomatic Mechanisms of Allostasis in Health and Disease.线粒体功能:在健康和疾病的身心适应机制的定义中处于前沿和中心位置。
Methods Mol Biol. 2025;2868:91-110. doi: 10.1007/978-1-0716-4200-9_6.
3
Protective Effects of Beta-3 Adrenoceptor Agonism on Mucosal Integrity in Hyperoxia-Induced Ileal Alterations.
β-3肾上腺素能受体激动对高氧诱导的回肠病变中黏膜完整性的保护作用。
Antioxidants (Basel). 2024 Jul 18;13(7):863. doi: 10.3390/antiox13070863.
4
Risks and side effects in the medical management of benign prostatic hyperplasia.良性前列腺增生症药物治疗中的风险与副作用
Prostate Int. 2024 Jun;12(2):57-64. doi: 10.1016/j.prnil.2023.11.004. Epub 2023 Dec 2.
5
Effect of a fixed combination of ripasudil and brimonidine on aqueous humor dynamics in mice.利帕舒地尔与溴莫尼定固定组合对小鼠房水动力学的影响。
Sci Rep. 2024 Apr 3;14(1):7861. doi: 10.1038/s41598-024-58212-6.
6
Inside the Biology of the β3-Adrenoceptor.β3-肾上腺素能受体的生物学特性
Biomolecules. 2024 Jan 29;14(2):159. doi: 10.3390/biom14020159.
7
Adrenoceptors in the Eye - Physiological and Pathophysiological Relevance.眼部肾上腺素能受体——生理与病理生理学相关性。
Handb Exp Pharmacol. 2024;285:453-505. doi: 10.1007/164_2023_702.
8
The Subtype Selectivity in Search of Potent Hypotensive Agents among 5,5-Dimethylhydantoin Derived α-Adrenoceptors Antagonists.5,5-二甲基海因衍生的α-肾上腺素受体拮抗剂中寻找强效降压药物的亚型选择性。
Int J Mol Sci. 2023 Nov 22;24(23):16609. doi: 10.3390/ijms242316609.
9
α-Adrenergic Receptor Blockade Inhibits Langendorff-Isolated Rat Heart Work.α-肾上腺素能受体阻断抑制离体Langendorff大鼠心脏的做功。
Bull Exp Biol Med. 2023 Sep;175(5):612-615. doi: 10.1007/s10517-023-05911-1. Epub 2023 Oct 21.
10
Noradrenergic alterations in Parkinson's disease: a combined 11C-yohimbine PET/neuromelanin MRI study.帕金森病中的去甲肾上腺素改变:11C-育亨宾 PET/神经黑色素 MRI 联合研究。
Brain. 2024 Apr 4;147(4):1377-1388. doi: 10.1093/brain/awad338.